A systematic review of reboxetine for treating patients with attention deficit hyperactivity disorder. (May 2015)

• Record Type: Journal Article
• Authors: Ghanizadeh, Ahmad
• Is Part Of: Nordic journal of psychiatry. Volume 69:Number 4(2015)
• Page Start: 241
• Page End: 248
• Publication Date: 2015-05
• Subjects: Psychopharmacology -- Periodicals; Psychotherapy -- Periodicals; Psychiatry -- Periodicals; Psychiatry -- Scandinavia -- Periodicals; 616.89
• DOI: 10.3109/08039488.2014.972975
• Languages: English
• ISSNs: 0803-9488

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background:</italic> No published systematic review has ever assessed the efficacy and safety of reboxetine for treating of patients with attention deficit hyperactivity disorder (ADHD). <italic>Aim:</italic> This systematic review aimed to review the available evidence regarding the efficacy of reboxetine for treating ADHD. <italic>Method:</italic> The databases of Pubmed/Medline, Google scholar, SCOPUS and Web of Science were searched using the Keywords: "reboxetine", "ADHD" and "attention deficit hyperactivity disorder". The reference lists of the included studies were screened to find any possible other relevant articles. All the non-controlled and controlled clinical trials were included. <italic>Results:</italic> The current evidence mainly consists of un-controlled studies, such as case series. Only three of 33 studies were controlled clinical trials. They are from single sites and included a sub-sample of patients with ADHD. <italic>Conclusion:</italic> Non-controlled studies and controlled trials support the promising effect of reboxetine for treating ADHD in a sub-sample of patients that are without co-morbid psychiatric disorder and mental retardation. Reboxetine is tolerated well. However, more controlled trials are needed to reach any firm conclusion.</p> </abstract>